Titre : Personnel de recherche

Personnel de recherche : Questions médicales fréquentes

Termes MeSH sélectionnés :

Interrupted Time Series Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Personnel de recherche : Questions médicales les plus fréquentes", "headline": "Personnel de recherche : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Personnel de recherche : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-07", "dateModified": "2025-04-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Personnel de recherche" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Groupes professionnels", "url": "https://questionsmedicales.fr/mesh/D009274", "about": { "@type": "MedicalCondition", "name": "Groupes professionnels", "code": { "@type": "MedicalCode", "code": "D009274", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "M01.526" } } }, "about": { "@type": "MedicalCondition", "name": "Personnel de recherche", "alternateName": "Research Personnel", "code": { "@type": "MedicalCode", "code": "D012108", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "I L Krom", "url": "https://questionsmedicales.fr/author/I%20L%20Krom", "affiliation": { "@type": "Organization", "name": "The Federal State Budget Educational Institution of Higher Education \"The V. I. Razumovsky Saratov State Medical University\" of Minzdrav of Russia, 410012, Saratov, Russia, irina.crom@yandex.ru." } }, { "@type": "Person", "name": "M V Erugina", "url": "https://questionsmedicales.fr/author/M%20V%20Erugina", "affiliation": { "@type": "Organization", "name": "The Federal State Budget Educational Institution of Higher Education \"The V. I. Razumovsky Saratov State Medical University\" of Minzdrav of Russia, 410012, Saratov, Russia." } }, { "@type": "Person", "name": "Luellen Fletcher", "url": "https://questionsmedicales.fr/author/Luellen%20Fletcher", "affiliation": { "@type": "Organization", "name": "Perelman School of Medicine Path BioResource University of Pennsylvania M163 John Morgan Bldg., 3620 Hamilton WalkPhiladelphiaPennsylvania19104 USA." } }, { "@type": "Person", "name": "Christina A Harrington", "url": "https://questionsmedicales.fr/author/Christina%20A%20Harrington", "affiliation": { "@type": "Organization", "name": "University Shared Resources and Knight Cancer Institute Oregon Health & Science University 3181 S.W. Sam Jackson Park RoadPortlandOregon97239 USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Interrupted time series analysis using the ARIMA model of the impact of COVID-19 on the incidence rate of notifiable communicable diseases in China.", "datePublished": "2023-06-05", "url": "https://questionsmedicales.fr/article/37316780", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12879-023-08229-5" } }, { "@type": "ScholarlyArticle", "name": "Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.", "datePublished": "2023-03-23", "url": "https://questionsmedicales.fr/article/36952213", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40259-023-00589-3" } }, { "@type": "ScholarlyArticle", "name": "Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.", "datePublished": "2023-05-22", "url": "https://questionsmedicales.fr/article/37271070", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugpo.2023.104075" } }, { "@type": "ScholarlyArticle", "name": "The impact of an annual mass media campaign on treatment seeking for alcohol use disorders in the Danish population: An interrupted time-series analysis.", "datePublished": "2023-05-05", "url": "https://questionsmedicales.fr/article/37224672", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugalcdep.2023.109910" } }, { "@type": "ScholarlyArticle", "name": "Impact of a performance monitoring intervention on the timeliness of Hepatitis B birth dose vaccination in the Gambia: a controlled interrupted time series analysis.", "datePublished": "2023-03-27", "url": "https://questionsmedicales.fr/article/36973797", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12889-023-15499-w" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Personnes", "item": "https://questionsmedicales.fr/mesh/D009272" }, { "@type": "ListItem", "position": 3, "name": "Groupes professionnels", "item": "https://questionsmedicales.fr/mesh/D009274" }, { "@type": "ListItem", "position": 4, "name": "Personnel de recherche", "item": "https://questionsmedicales.fr/mesh/D012108" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Personnel de recherche - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Personnel de recherche", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Personnel de recherche", "description": "Comment évaluer l'efficacité d'un traitement ?\nQuelles méthodes de recherche sont utilisées ?\nComment identifier les biais dans une étude ?\nQu'est-ce qu'une revue systématique ?\nComment mesurer la validité d'un test ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=11#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Personnel de recherche", "description": "Quels symptômes surveiller lors d'une étude ?\nComment évaluer les effets secondaires ?\nQuels indicateurs de santé sont mesurés ?\nComment documenter les symptômes des participants ?\nQuelle est l'importance des auto-évaluations ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=11#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Personnel de recherche", "description": "Quelles stratégies de prévention sont utilisées ?\nComment évaluer l'impact des programmes de prévention ?\nQuels facteurs influencent la prévention ?\nComment sensibiliser à la prévention ?\nQuelle est l'importance du dépistage précoce ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=11#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Personnel de recherche", "description": "Comment choisir un traitement dans une étude ?\nQuelles sont les approches de traitement courantes ?\nComment évaluer l'adhérence au traitement ?\nQuels sont les critères d'évaluation des traitements ?\nComment gérer les traitements combinés ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=11#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Personnel de recherche", "description": "Quelles complications peuvent survenir dans les études ?\nComment gérer les complications dans une étude ?\nQuels sont les risques associés aux traitements ?\nComment évaluer les complications post-traitement ?\nQuelle est l'importance de la déclaration des complications ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=11#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Personnel de recherche", "description": "Quels sont les facteurs de risque courants ?\nComment identifier les facteurs de risque dans une étude ?\nQuel rôle joue l'environnement dans les risques ?\nComment évaluer l'impact des facteurs de risque ?\nQuelle est l'importance de la prévention des risques ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=11#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'efficacité d'un traitement ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par des études cliniques contrôlées et des analyses statistiques." } }, { "@type": "Question", "name": "Quelles méthodes de recherche sont utilisées ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent les essais randomisés, les études de cohorte et les méta-analyses." } }, { "@type": "Question", "name": "Comment identifier les biais dans une étude ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les biais peuvent être identifiés par l'examen des méthodes de sélection et d'analyse des données." } }, { "@type": "Question", "name": "Qu'est-ce qu'une revue systématique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "C'est une synthèse des études existantes sur un sujet, évaluant la qualité des preuves." } }, { "@type": "Question", "name": "Comment mesurer la validité d'un test ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La validité est mesurée par la sensibilité, la spécificité et la valeur prédictive." } }, { "@type": "Question", "name": "Quels symptômes surveiller lors d'une étude ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon l'étude, mais incluent souvent douleur, fatigue et dysfonction." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires sont évalués par des questionnaires et des rapports de patients." } }, { "@type": "Question", "name": "Quels indicateurs de santé sont mesurés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les indicateurs incluent la pression artérielle, le taux de cholestérol et les marqueurs biologiques." } }, { "@type": "Question", "name": "Comment documenter les symptômes des participants ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes sont documentés par des journaux de santé et des évaluations cliniques régulières." } }, { "@type": "Question", "name": "Quelle est l'importance des auto-évaluations ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les auto-évaluations fournissent des informations précieuses sur l'état de santé perçu par le patient." } }, { "@type": "Question", "name": "Quelles stratégies de prévention sont utilisées ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les stratégies incluent l'éducation, les vaccinations et les dépistages réguliers." } }, { "@type": "Question", "name": "Comment évaluer l'impact des programmes de prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'impact est évalué par des études de suivi et des analyses de données de santé publique." } }, { "@type": "Question", "name": "Quels facteurs influencent la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'accès aux soins, le niveau d'éducation et les comportements de santé." } }, { "@type": "Question", "name": "Comment sensibiliser à la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "La sensibilisation se fait par des campagnes d'information, des ateliers et des médias sociaux." } }, { "@type": "Question", "name": "Quelle est l'importance du dépistage précoce ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage précoce permet d'identifier les maladies à un stade précoce, améliorant les résultats." } }, { "@type": "Question", "name": "Comment choisir un traitement dans une étude ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le choix est basé sur des critères d'inclusion, des protocoles et des résultats antérieurs." } }, { "@type": "Question", "name": "Quelles sont les approches de traitement courantes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les approches incluent la pharmacothérapie, la thérapie physique et les interventions chirurgicales." } }, { "@type": "Question", "name": "Comment évaluer l'adhérence au traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'adhérence est évaluée par des questionnaires, des entretiens et des suivis réguliers." } }, { "@type": "Question", "name": "Quels sont les critères d'évaluation des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent l'efficacité, la sécurité, la tolérance et la qualité de vie." } }, { "@type": "Question", "name": "Comment gérer les traitements combinés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements combinés nécessitent une évaluation rigoureuse des interactions et des effets cumulés." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir dans les études ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des effets indésirables, des non-conformités et des biais d'étude." } }, { "@type": "Question", "name": "Comment gérer les complications dans une étude ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique une surveillance étroite, des ajustements de protocole et des rapports transparents." } }, { "@type": "Question", "name": "Quels sont les risques associés aux traitements ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des réactions allergiques, des interactions médicamenteuses et des complications chirurgicales." } }, { "@type": "Question", "name": "Comment évaluer les complications post-traitement ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont évaluées par des suivis cliniques et des questionnaires de satisfaction." } }, { "@type": "Question", "name": "Quelle est l'importance de la déclaration des complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La déclaration permet d'améliorer la sécurité des patients et d'affiner les protocoles de recherche." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque courants ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le sexe, les antécédents médicaux et les habitudes de vie." } }, { "@type": "Question", "name": "Comment identifier les facteurs de risque dans une étude ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs sont identifiés par des questionnaires, des entretiens et des analyses de données." } }, { "@type": "Question", "name": "Quel rôle joue l'environnement dans les risques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'environnement influence les risques par l'exposition à des toxines, des infections et des comportements." } }, { "@type": "Question", "name": "Comment évaluer l'impact des facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "L'impact est évalué par des études épidémiologiques et des analyses statistiques." } }, { "@type": "Question", "name": "Quelle est l'importance de la prévention des risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "La prévention réduit l'incidence des maladies et améliore la santé publique globale." } } ] } ] }

Sources (10000 au total)

Interrupted time series analysis using the ARIMA model of the impact of COVID-19 on the incidence rate of notifiable communicable diseases in China.

The coronavirus disease 2019 (COVID-19) pandemic in China is ongoing. Some studies have shown that the incidence of respiratory and intestinal infectious diseases in 2020 decreased significantly compa... National data on the incidence rate of communicable diseases in 2009-2021 were obtained from the National Health Commission website. Interrupted time series analysis using autoregressive integrated mo... There was a significant short-term decline in the incidence rates of respiratory infectious diseases and enteric infectious diseases (step values of -29.828 and - 8.237, respectively), which remained ... The COVID-19 epidemic had strong short-term and long-term effects on respiratory and intestinal infectious diseases and short-term control effects on blood-borne and sexually transmitted infectious di...

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.

We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the origi... An interrupted time series analysis using infliximab sales data from 2010 to 2020 from the IQVIA Multinational Integrated Data Analysis System for eight selected regions: Australia, Canada, Hong Kong,... Following the introduction of infliximab biosimilars, overall infliximab consumption increased in Australia [immediate change: 0.145 SU/1000 inhabitants (P = 0.014); long-term change: 0.022 SU/1000 in... Introduction of the first infliximab biosimilar was not consistently associated with increased consumption across regions. Additional policy and healthcare system interventions to support biosimilar i...

Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.

In anticipation of COVID-19 related disruptions to opioid use disorder (OUD) care, new provincial and federal guidance for the management of OUD and risk mitigation guidance (RMG) for prescription of ... Using data from three cohorts of people with presumed OUD in Vancouver, we conducted an interrupted time series analysis to estimate the combined effects impact of the COVID-19 pandemic and counteract... We included 760 participants with presumed OUD. In the post-COVID-19 period, MOUD and slow-release oral morphine prevalence rates showed an estimated immediate increase in level (+7.6%, 95% CI: 0.6%, ... Despite immediate improvements in MOUD enrollment in the post-COVID-19 period, this beneficial trend reversed over time. RMG opioids appeared to have provided additional benefits to sustain retention ...

The impact of an annual mass media campaign on treatment seeking for alcohol use disorders in the Danish population: An interrupted time-series analysis.

A minority of individuals with alcohol use disorder (AUD) seek treatment. In Denmark, a mass media campaign, "RESPEKT", aiming to increase treatment seeking, has been broadcasted nationwide since 2015... To investigate whether there was an association between campaign periods and treatment seeking for AUD. A secondary aim was to investigate possible gender differences. The hypotheses were that treatme... Study design: Interrupted time-series analysis.... Adults aged 18 years and above in the Danish population seeking AUD treatment.... Campaign periods year 2015-2018.... Changes in treatment seeking defined as treatment entry respectively filled prescription of AUD pharmacotherapy.... National Alcohol Treatment Register on treatment entries for specialist addiction care and National Prescription Registry for filled prescriptions on AUD pharmacotherapies 2013-2018.... Segmented negative binomial regression, including the full cohort and stratified by sex.... The results show no association between campaign periods and treatment seeking. Nor were there any gender differences in treatment seeking. The hypotheses were not confirmed.... The campaign periods showed no association with treatment seeking. Eventual future campaigns should possibly focus on earlier steps of the treatment seeking process, as problem recognition, to increas...

Impact of a performance monitoring intervention on the timeliness of Hepatitis B birth dose vaccination in the Gambia: a controlled interrupted time series analysis.

The Hepatitis B virus that can cause liver cancer is highly prevalent in the Gambia, with one in ten babies at risk of infection from their mothers. Timely hepatitis B birth dose administration to pro... We used a controlled interrupted time series design including 16 intervention health facilities and 13 matched controls monitored from February 2019 to December 2020. The intervention comprised a mont... Overall, birth dose timeliness improved in the intervention compared to control health facilities. This intervention impact was, however, dependent on pre-intervention health facility performance, wit... The implementation of a novel hepatitis B vaccination timeliness monitoring system in health facilities led to overall improvements in both immediate timeliness rate and trend, and was especially help...

Assessing the impact of a national clinical guideline for the management of chronic pain on opioid prescribing rates: a controlled interrupted time series analysis.

Opioids can be effective analgesics, but long-term use may be associated with harms. In 2013, the first national, comprehensive, evidence-based pain management guideline was published, from the Scotti... Trends in national and regional community opioid prescribing data for Scotland were analysed from quarter one (Q1) 2005 to Q2 2020. Interrupted time series regression examined the association of SIGN ... After a positive prescribing trend pre-publication, the timing of SIGN 136 publication was associated with a negative change in the trend of opioid prescribing rates (-2.82 items per 1000 population p... The publication of SIGN 136 was associated with a reduction in opioid prescribing rates. This suggests that changes in clinical policy through evidence-based national clinical guidelines may affect co...

Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A population-based interrupted time series analysis.

In November 2013, the Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease was published, recommending statins for all individuals 50 ye...

The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis.

To reduce the burden of patients' medical care, the Xuzhou Municipal Government has initiated an exploratory study on the supply model and categorized management of nationally negotiated drugs. This s... The Interrupted Time Series Analysis method was adopted, and the changes in average medical expenses per patient, average medical insurance payment cost per patient and actual reimbursement ratio were... Following the implementation of the policy, there was a significant decrease in the average medical expenses per patient of national drug negotiation in Xuzhou, with a reduction of 62.42 yuan per mont... After the adoption of the NDPN policy, a noticeable decline has been observed in the average medical expenses per patient and the mean cost of the average medical insurance payment per patient, althou...

Impact of a Finnish reform adding new sickness absence checkpoints on rehabilitation and labor market outcomes: an interrupted time series analysis.

In 2012, new checkpoints were introduced in the Finnish sickness absence system to improve early detection of long-term work disability and hasten return to work after illness. We examined whether the... We used interrupted time series analysis among persons who started receiving sickness allowance up to three years before and up to two years after the reform. Separate analyses were conducted among th... After the reform, participation in rehabilitation within one year of passing 30 sickness allowance days increased by 5.1% [incidence rate ratio (IRR) 1.051, 95% confidence interval (CI) 1.015-1.086]. ... The introduction of new sickness absence checkpoints was associated with an increase in participation in rehabilitation but did not affect labor market outcomes one year later. The reform thus was onl...